Wnt signaling pathway protein (Wnt)

Wnt signaling pathway proteins represent a large family of secreted, cysteine-rich glycoproteins—collectively termed Wnt proteins—that act as morphogens to orchestrate diverse cellular processes through both canonical (β-catenin–dependent) and non-canonical (β-catenin–independent) signaling cascades[5][7][1]. The Wnt family includes over 19 ligands in humans (e.g., Wnt1, Wnt3a, Wnt5a), which bind primarily to Frizzled (FZD) receptors and co-receptors such as LRP5/6 to stimulate intracellular pathways governing cell fate determination, proliferation, migration, apoptosis, and stem cell renewal[5][7]. Dysregulation of Wnt signaling underpins numerous diseases, especially cancer, where excessive or constitutive activation drives tumor initiation, progression, metastasis, and modulation of the tumor microenvironment[4][5][7]. While individual Wnt ligands and their effectors (such as β-catenin or specific Frizzled receptors) are valid therapeutic targets, “Wnt signaling pathway proteins” as a group constitutes a heterogeneous set rather than a single drug target. Multiple small molecules, biologics, and natural products have been developed to either inhibit or mimic Wnt pathway components. However, clinical translation is challenged by the pathway’s pleiotropic roles, potential off-target toxicities, and oncogenicity risks associated with therapeutic manipulation[3][1][5].\n\n**Note:** \n- The query “Wnt signaling pathway proteins” is overly broad and refers to a class of more than 19 related secreted proteins, rather than a single molecular target. For structured data and drug discovery, individual Wnt ligands (e.g., “Wnt3a”), receptors (e.g., “Frizzled-7”), or core signaling effectors (e.g., “β-catenin”) are preferred canonical entries for drug targeting. Therefore, “Wnt signaling pathway protein” is not a precise canonical drug target and is marked as “is_incorrect: true.” \n- If a specific ligand, receptor, or effector within the pathway is of interest, it is advisable to specify (e.g., “Wnt3a,” “Frizzled-7 receptor,” or “β-catenin”).

Other names

Wnt pathway proteinsWnt proteinsWnt ligandsWnt/β-catenin componentsWnt signaling components

Inhibition of Wnt ligand secretion, Inhibition of Frizzled receptor binding, Inhibition of β-catenin–TCF interaction, Antagonism of co-receptors (LRP5/6), Tankyrase inhibition, GSK-3β inhibition, Disruption of Wnt ligand maturation (Porcupine inhibition), Monoclonal antibody blockade